Published on 23 Apr 2024 on Zacks via Yahoo Finance
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
Vertex Pharmaceuticals Incorporated VRTX announced that it has entered into a licensing and collaboration agreement with France-based biotech company, TreeFrog Therapeutics, to optimize the production of VRTX's type 1 diabetes (T1D) cell therapies.
The agreement will grant the pharmaceutical company an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-Stem, which will be leveraged by VRTX to enhance its ability to generate large amounts of fully differentiated insulin-producing pancreatic islet cells for its portfolio of T1D cell therapies.